NORD To Honor Rare Disease Heroes At 30th Anniversary Celebration
Momentous Event to Highlight Historic Past, Promising Future
“Since 1983, the rare disease community, with NORD as a unifying force, has built a solid foundation of accomplishment,” said NORD President and CEO
The Orphan Drug Act of 1983 launched a new era in the development of therapies for people with rare diseases. Established by patient advocates at the time the law was enacted, NORD has been at the heart of rare disease activity over the years, working with partners in patient organizations, government and industry to bring meaningful advancements for patients.
Honorees for the NORD 30(th) Anniversary Celebration will be:
For Leadership in Public Policy
These awards honor public officials for leadership that has improved the lives of millions of Americans living with rare diseases.
William Corr, Deputy Secretary, U.S. Department of Health and Human Services
- The Honorable Nancy Kassebaum, U.S. Senate, retired
- The Honorable Henry Waxman, U.S. House of Representatives
For Vision and Pioneering Guidance
These awards honor pioneers in the patient community, government and industry for years of service to rare disease patients and their families.
Stephen C. Groft, PharmD
Marlene Haffner, MD, MPH
Lars Uno Larsson
Abbey S. Meyers
Jess G. Thoene, MD
For Innovative Orphan Products Approved in 2012
These awards honor companies that brought important and innovative treatments to market during the previous year.
- Aegerion Pharmaceuticals, Inc.
- NPS Pharmaceuticals, Inc.
- Onyx Pharmaceuticals, Inc.
- Sigma-Tau Pharmaceuticals, Inc.
REGISTRATION AND SPONSORSHIP
SOURCE National Organization for Rare Disorders (NORD)